Dr. Ashish Kamat highlights how standardized trial design from the SITC-IBCG consensus has improved consistency in NMIBC research, while emphasizing that patient-centered outcomes like long-term cancer-free survival remain key. He also notes growing interest in bladder preservation, supported by advances in monitoring and salvage strategies, but caution that it should still be pursued within clinical trials rather than routine practice. Ultimately, the field is moving toward more personalized care aiming to match the right treatment, bladder-sparing or cystectomy, to the right patient.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
